[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Black Diamond Therapeutics Inc (BDTX)

Black Diamond Therapeutics Inc (BDTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 130,649
  • Shares Outstanding, K 57,302
  • Annual Sales, $ 70,000 K
  • Annual Income, $ 22,370 K
  • EBIT $ -46 M
  • EBITDA $ -46 M
  • 60-Month Beta 3.34
  • Price/Sales 2.91
  • Price/Cash Flow 6.73
  • Price/Book 1.95

Options Overview Details

View History
  • Implied Volatility 110.40% (-81.45%)
  • Historical Volatility 161.43%
  • IV Percentile 11%
  • IV Rank 14.92%
  • IV High 435.97% on 03/03/26
  • IV Low 53.32% on 08/19/25
  • Expected Move (DTE 26) 0.47 (20.50%)
  • Put/Call Vol Ratio 0.21
  • Today's Volume 12,125
  • Volume Avg (30-Day) 2,028
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 18,761
  • Open Int (30-Day) 14,071
  • Expected Range 1.81 to 2.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.18
  • Number of Estimates 5
  • High Estimate $-0.14
  • Low Estimate $-0.22
  • Prior Year $-0.19
  • Growth Rate Est. (year over year) +5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.25 +1.33%
on 05/22/26
3.97 -42.57%
on 05/20/26
-1.07 (-31.94%)
since 04/22/26
3-Month
1.93 +18.13%
on 03/06/26
3.97 -42.57%
on 05/20/26
-0.05 (-2.15%)
since 02/20/26
52-Week
1.93 +18.13%
on 03/06/26
4.94 -53.85%
on 11/12/25
+0.22 (+10.68%)
since 05/22/25

Most Recent Stories

More News
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...

BDTX : 2.28 (-35.77%)
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study

Black Diamond Therapeutics (NASDAQ:BDTX) reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigational...

BDTX : 2.28 (-35.77%)
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

Preliminary mPFS of 15.2 months; mDOR not reached Robust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastases ORR 60% in patients with a broad spectrum of EGFR-NCMs, including...

BDTX : 2.28 (-35.77%)
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company...

BDTX : 2.28 (-35.77%)
Black Diamond: Q1 Earnings Snapshot

Black Diamond: Q1 Earnings Snapshot

BDTX : 2.28 (-35.77%)
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual Meeting First patient dosed in the Phase...

BDTX : 2.28 (-35.77%)
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients...

BDTX : 2.28 (-35.77%)
Black Diamond: Q4 Earnings Snapshot

Black Diamond: Q4 Earnings Snapshot

BDTX : 2.28 (-35.77%)
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Clinical update on track for Q2 2026 for Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, including preliminary DOR and PFS data in frontline setting Company is preparing to...

BDTX : 2.28 (-35.77%)
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic...

BDTX : 2.28 (-35.77%)

Business Summary

Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor...

See More

Key Turning Points

3rd Resistance Point 3.64
2nd Resistance Point 3.36
1st Resistance Point 2.82
Last Price 2.28
1st Support Level 2.00
2nd Support Level 1.71
3rd Support Level 1.17

See More

52-Week High 4.94
Fibonacci 61.8% 3.79
Fibonacci 50% 3.43
Fibonacci 38.2% 3.08
Last Price 2.28
52-Week Low 1.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.